Scarica l'app Stockscreener
15.13
0.20%
0.03
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ROIV Giù?
Forum
Previsione
Precedente Chiudi:
$15.10
Aprire:
$15.05
Volume 24 ore:
6.26M
Relative Volume:
0.94
Capitalizzazione di mercato:
$10.33B
Reddito:
$125.68M
Utile/perdita netta:
$4.81B
Rapporto P/E:
2.6779
EPS:
5.65
Flusso di cassa netto:
$-781.21M
1 W Prestazione:
+2.65%
1M Prestazione:
+26.82%
6M Prestazione:
+49.95%
1 anno Prestazione:
+31.11%
Intervallo 1D:
$14.93
$15.27
Intervallo di 1 settimana:
$14.50
$15.28
Portata 52W:
$8.73
$16.05
Roivant Sciences Ltd Stock (ROIV) Company Profile
Nome
Roivant Sciences Ltd
Settore
Industria
Telefono
441-295-5950
Indirizzo
7TH FLOOR, 50 BROADWAY, LONDON
Confronta ROIV con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ROIV
Roivant Sciences Ltd
|
15.13 | 10.31B | 125.68M | 4.81B | -781.21M | 5.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.64 | 101.35B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.00 | 58.66B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
562.27 | 59.43B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
737.56 | 44.01B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
340.70 | 36.56B | 3.81B | -644.79M | -669.77M | -6.24 |
Roivant Sciences Ltd Stock (ROIV) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-02 | Iniziato | Citigroup | Buy |
| 2025-07-10 | Ripresa | Goldman | Buy |
| 2024-02-15 | Iniziato | Wolfe Research | Outperform |
| 2024-01-05 | Iniziato | Piper Sandler | Overweight |
| 2023-12-12 | Iniziato | Deutsche Bank | Buy |
| 2023-10-17 | Iniziato | Guggenheim | Buy |
| 2023-06-08 | Iniziato | BofA Securities | Neutral |
| 2022-10-27 | Iniziato | JP Morgan | Overweight |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2022-04-29 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-12-15 | Iniziato | Goldman | Buy |
| 2021-11-08 | Iniziato | H.C. Wainwright | Buy |
| 2021-10-28 | Iniziato | Citigroup | Buy |
| 2021-10-26 | Iniziato | Cowen | Outperform |
| 2021-10-26 | Iniziato | Jefferies | Buy |
| 2021-10-26 | Iniziato | Truist | Buy |
Mostra tutto
Roivant Sciences Ltd Borsa (ROIV) Ultime notizie
Can Roivant Sciences Ltd. (87S) stock double in coming yearsQuarterly Profit Summary & AI Enhanced Trading Signals - newser.com
Will Roivant Sciences Ltd. continue its uptrendEarnings Recap Report & Fast Moving Stock Watchlists - newser.com
Roivant Sciences stock poised for growth, Goldman Sachs reiterates Buy By Investing.com - Investing.com South Africa
Roivant Sciences stock poised for growth, Goldman Sachs reiterates Buy - Investing.com India
Roivant Sciences Ltd.’s volatility index tracking explainedGap Up & Growth Focused Stock Reports - newser.com
Is Roivant Sciences Ltd. (87S) stock undervalued historicallyMarket Activity Summary & AI Driven Stock Price Forecasts - newser.com
Why retail investors pile into Roivant Sciences Ltd. stockBond Market & Real-Time Stock Price Movement Reports - newser.com
Why Roivant Sciences Ltd. (87S) stock attracts wealthy investorsOil Prices & Accurate Technical Buy Alerts - newser.com
What sentiment indicators say about Roivant Sciences Ltd. stockProfit Target & Risk Controlled Stock Alerts - newser.com
Long term hold vs stop loss in Roivant Sciences Ltd.Trade Analysis Report & Long-Term Safe Investment Plans - newser.com
LVW Advisors LLC Makes New $199,000 Investment in Roivant Sciences Ltd. $ROIV - MarketBeat
Can Roivant Sciences Ltd. stock deliver consistent earnings growth2025 Price Action Summary & Expert Curated Trade Ideas - newser.com
What analysts say about Roivant Sciences Ltd stockDividend Stability Analysis & Fast Growing Investment Ideas - earlytimes.in
How Investors May Respond To Roivant Sciences (ROIV) Positive Phase 3 Results for Brepocitinib in Dermatomyositis - simplywall.st
Roivant Sciences Ltd. (NASDAQ:ROIV) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
Is Roivant Sciences Ltd a good long term investmentVolatility Index Analysis & These Stocks Are Just Getting Started - Early Times
Transcript : Roivant Sciences Ltd. Presents at Bernstein 2nd Annual Global Healthcare Conference, Sep-23-2025 01 - MarketScreener
Transcript : Roivant Sciences Ltd. Presents at Bank of America Global Healthcare Conference 2025, Sep-24-2025 09 - MarketScreener
Roivant Sciences president Venker sells $25.5m in shares By Investing.com - ng.investing.com
Roivant Sciences at Bank of America Global Healthcare: Strategic Insights By Investing.com - Investing.com Australia
analysts-double-sales-forecasts-for-roivant-s-brepocitinib-after-trial-success-93143405 - S&P Global
Roivant Sciences (NASDAQ:ROIV) CEO Eric Venker Sells 611,000 Shares - MarketBeat
Roivant Sciences (NASDAQ:ROIV) CEO Eric Venker Sells 416,182 Shares - MarketBeat
Roivant Sciences president Venker sells $25.5m in shares - Investing.com
Are You Looking for a Top Momentum Pick? Why Roivant Sciences Ltd. (ROIV) is a Great Choice - Yahoo Finance
Roivant Sciences (NASDAQ:ROIV) Given New $22.00 Price Target at Leerink Partners - MarketBeat
Inspire Investing LLC Invests $303,000 in Roivant Sciences Ltd. $ROIV - MarketBeat
The Goldman Sachs Group Boosts Roivant Sciences (NASDAQ:ROIV) Price Target to $24.00 - MarketBeat
Roivant Sciences (NASDAQ:ROIV) Price Target Raised to $20.00 at HC Wainwright - MarketBeat
Bank of America Forecasts Strong Price Appreciation for Roivant Sciences (NASDAQ:ROIV) Stock - MarketBeat
Roivant Sciences (NASDAQ:ROIV) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says - MarketBeat
Guggenheim Boosts Roivant Sciences (NASDAQ:ROIV) Price Target to $21.00 - MarketBeat
Ramaswamy-backed Strive to buy Semler in $1.3 billion deal all stock deal, boosting Bitcoin holdings - Reuters
What is HC Wainwright's Forecast for ROIV Q1 Earnings? - MarketBeat
Leerink Partnrs Has Bullish Estimate for ROIV Q2 Earnings - MarketBeat
Roivant Sciences (NASDAQ:ROIV) Hits New 1-Year HighWhat's Next? - MarketBeat
Roivant Sciences Hits Day High with Strong 7.76% Intraday Surge - Markets Mojo
Roivant Sciences (NASDAQ:ROIV) CEO Matthew Gline Purchases 3,315 Shares - MarketBeat
Roivant Sciences (ROIV): Assessing Valuation After Positive Phase 3 Brepocitinib Results in Dermatomyositis Trial - simplywall.st
History Review: Will Roivant Sciences Ltd benefit from rate cutsOptions Play & Weekly Watchlist for Hot Stocks - خودرو بانک
Ramaswamy Sells $23 Million of Roivant Sciences Stock -- Barron's - 富途牛牛
Roivant Sciences Ltd Azioni (ROIV) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.36%
1.10%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):